Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2019-03-19 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Board Meeting — Other business matters
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 57 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2019-03-19 English
Updates
Regulatory Filings
2019-03-12 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to the National Stock Exchange of India Limited regarding the resignation of an Independent Director, Mr. Nipun Arora, from Beta Drugs Limited. It references Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements), 2015, which pertains to disclosures about changes in the board of directors or senior management. The content includes the resignation letter itself and is clearly about a change in the company's board composition. There is no financial data, earnings information, or report publication mentioned. The document is short (2019 characters) and is a direct announcement of a management change, not a report or presentation. Therefore, the appropriate classification is Board/Management Information (MANG).
2019-02-22 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited reporting the outcome of a Board Meeting held on 4th February 2019. It details specific decisions made by the Board, such as approving an investment and granting a loan to a subsidiary. The content is an announcement of board decisions rather than a full report or financial statement. The document length is short (1485 characters), and it is clearly an announcement of board meeting outcomes, which fits the category of Board/Management Information (MANG).
2019-02-04 English
Updates
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or financial data. It is extremely short (242 characters) and does not provide any substantive information or report content. Given the lack of any report or announcement text, it cannot be classified as a financial report or announcement. It is best classified as a Regulatory Filing (RNS) as a fallback category for documents that do not fit other specific types.
2019-01-31 English
Board Meeting — Other business matters
Board/Management Information Classification · 90% confidence The document is a short notice informing about the scheduling of a Board Meeting to consider and approve an investment by a subsidiary. It does not contain financial statements or detailed financial data. The length is only 755 characters, indicating it is a brief announcement rather than a full report. The content focuses on notifying the exchange about the upcoming board meeting and its agenda, which aligns with Board/Management Information filings that announce changes or meetings of the board or senior management.
2019-01-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.